A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
<p>Abstract</p> <p>Background</p> <p>The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a l...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-06-01
|
Series: | Journal of Ovarian Research |
Online Access: | http://www.ovarianresearch.com/content/5/1/17 |
id |
doaj-9a14bb34d5704ea79eee864089af34ad |
---|---|
record_format |
Article |
spelling |
doaj-9a14bb34d5704ea79eee864089af34ad2020-11-25T00:37:53ZengBMCJournal of Ovarian Research1757-22152012-06-01511710.1186/1757-2215-5-17A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancerCarlotta DefferrariSara CamporaMauro D'AmicoArnoldo PiccardoEnnio BiscaldiDaniela RosselliAmbra PasaMatteo PuntoniAlberto GozzaAlessandra GennariSilvia ZanardiRita LionettoMichela BandelloniAndrea DeCensi<p>Abstract</p> <p>Background</p> <p>The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a lower dose of bevacizumab in pretreated advanced stage EOC.</p> <p>Methods</p> <p>We treated 15 patients, mostly with platinum resistant EOC, who had received a median of four prior cytotoxic regimens, with bevacizumab 5–7.5 mg/kg q21 days in combination with either carboplatin (n = 8), oral cyclofosfamide (n = 5) or weekly paclitaxel (n = 2). Bevacizumab was administered until disease progression. Tumor response was assessed by CA125 and fusion <sup>18</sup> F-FDG PET/contrast enhanced CT.</p> <p>Results</p> <p>The median number of bevacizumab cycles was 21 (range 3–59). The median baseline CA125 was 272 U/ml and decreased to 15.2 U/ml at nadir. Tumor response was 4 complete response (CR) (26.7%) and 7 partial response (PR) (46.7%) by chemotherapy (CT), with an overall response rate of 73.4% (95% CI, 51.0 – 95.8) according to Response Evaluation Criteria In Solid Tumors (RECIST), and 6 CR (40%) and 4 PR (26.7%) by PET, for an overall metabolic response rate of 67% (95%CI, 42.8 – 90.6) according to PET Response Criteria in Solid Tumors (PERCIST). Median progression free survival (PFS) was 21 months and median overall survival (OS) was 24 months. Grade 3 adverse events related to bevacizumab were hypertension (n = 2), proteinuria (n = 1) and epistaxis (n = 5). Treatment was delayed in five patients for nasal bleeding or uncontrolled hypertension.</p> <p>Conclusions</p> <p>Low-dose bevacizumab and chemotherapy was well tolerated and active in a heavily pretreated population of advanced EOC. Further studies should assess the activity of low dose bevacizumab in EOC.</p> http://www.ovarianresearch.com/content/5/1/17 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carlotta Defferrari Sara Campora Mauro D'Amico Arnoldo Piccardo Ennio Biscaldi Daniela Rosselli Ambra Pasa Matteo Puntoni Alberto Gozza Alessandra Gennari Silvia Zanardi Rita Lionetto Michela Bandelloni Andrea DeCensi |
spellingShingle |
Carlotta Defferrari Sara Campora Mauro D'Amico Arnoldo Piccardo Ennio Biscaldi Daniela Rosselli Ambra Pasa Matteo Puntoni Alberto Gozza Alessandra Gennari Silvia Zanardi Rita Lionetto Michela Bandelloni Andrea DeCensi A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer Journal of Ovarian Research |
author_facet |
Carlotta Defferrari Sara Campora Mauro D'Amico Arnoldo Piccardo Ennio Biscaldi Daniela Rosselli Ambra Pasa Matteo Puntoni Alberto Gozza Alessandra Gennari Silvia Zanardi Rita Lionetto Michela Bandelloni Andrea DeCensi |
author_sort |
Carlotta Defferrari |
title |
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
title_short |
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
title_full |
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
title_fullStr |
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
title_full_unstemmed |
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
title_sort |
case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer |
publisher |
BMC |
series |
Journal of Ovarian Research |
issn |
1757-2215 |
publishDate |
2012-06-01 |
description |
<p>Abstract</p> <p>Background</p> <p>The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a lower dose of bevacizumab in pretreated advanced stage EOC.</p> <p>Methods</p> <p>We treated 15 patients, mostly with platinum resistant EOC, who had received a median of four prior cytotoxic regimens, with bevacizumab 5–7.5 mg/kg q21 days in combination with either carboplatin (n = 8), oral cyclofosfamide (n = 5) or weekly paclitaxel (n = 2). Bevacizumab was administered until disease progression. Tumor response was assessed by CA125 and fusion <sup>18</sup> F-FDG PET/contrast enhanced CT.</p> <p>Results</p> <p>The median number of bevacizumab cycles was 21 (range 3–59). The median baseline CA125 was 272 U/ml and decreased to 15.2 U/ml at nadir. Tumor response was 4 complete response (CR) (26.7%) and 7 partial response (PR) (46.7%) by chemotherapy (CT), with an overall response rate of 73.4% (95% CI, 51.0 – 95.8) according to Response Evaluation Criteria In Solid Tumors (RECIST), and 6 CR (40%) and 4 PR (26.7%) by PET, for an overall metabolic response rate of 67% (95%CI, 42.8 – 90.6) according to PET Response Criteria in Solid Tumors (PERCIST). Median progression free survival (PFS) was 21 months and median overall survival (OS) was 24 months. Grade 3 adverse events related to bevacizumab were hypertension (n = 2), proteinuria (n = 1) and epistaxis (n = 5). Treatment was delayed in five patients for nasal bleeding or uncontrolled hypertension.</p> <p>Conclusions</p> <p>Low-dose bevacizumab and chemotherapy was well tolerated and active in a heavily pretreated population of advanced EOC. Further studies should assess the activity of low dose bevacizumab in EOC.</p> |
url |
http://www.ovarianresearch.com/content/5/1/17 |
work_keys_str_mv |
AT carlottadefferrari acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT saracampora acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT maurodamico acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT arnoldopiccardo acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT enniobiscaldi acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT danielarosselli acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT ambrapasa acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT matteopuntoni acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT albertogozza acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT alessandragennari acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT silviazanardi acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT ritalionetto acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT michelabandelloni acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT andreadecensi acaseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT carlottadefferrari caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT saracampora caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT maurodamico caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT arnoldopiccardo caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT enniobiscaldi caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT danielarosselli caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT ambrapasa caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT matteopuntoni caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT albertogozza caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT alessandragennari caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT silviazanardi caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT ritalionetto caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT michelabandelloni caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer AT andreadecensi caseseriesoflowdosebevacizumabandchemotherapyinheavilypretreatedpatientswithepithelialovariancancer |
_version_ |
1725299171721740288 |